Skip to main content
. 2023 Sep 14;13:1247291. doi: 10.3389/fonc.2023.1247291

Figure 3.

Figure 3

Administration of dostarlimab in Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) centers in 2021 and 2022.